The use of human monoclonal antibody to detect serum antigen in patients with breast cancer.

The human monoclonal antibody JDBI has been utilized in retrospective studies to identify serum antigens in breast cancer patients. Using both rapid latex slide agglutination and enzyme immunoassay techniques, studies of over 200 breast cancer patients and 400 controls have suggested that the presence of serum antigens identified by this antibody, may be related to disease activity. Eighty-eight percent of patients with active metastatic breast cancer are found to be antigen positive. More importantly, these tests appear to identify tumorogenic activity in women in remission of their disease, and may detect metastatic disease before it is identifiable using currently available routine tests. Consequently, these assays may provide valuable and as yet unavailable information about the progress of patients with breast cancer.